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Determinants of Doppler Pulmonary
Flow Components
Recently, CP Appelton presented an elegant animal study on the
hemodynamic determinants of Doppler pulmonary venous flow veloc-
ity components (1). One of the conclusions was that the late systolic
pressure increase in the pulmonary vein system was a direct result of
the right ventricular stroke volume. The late systolic component of the
pulmonary venous flow curve was a direct result of the right heart
filling the pulmonary veins and left atrium.
Patients with univentricular hearts palliated with a Fontan or total
cavopulmonary connection (TCPC) procedure do have a circulation
where the systemic ventricle is the only ventricle causing pressure on
the total circuit (i.e., there is no right ventricle giving a pressure head
for the pulmonary circulation which is then dependant on the systemic
venous pressure). We examined a group of patients with a TCPC
circulation and found the same pulmonary venous flow patterns as
seen in biventricular hearts with four phases: atrial reversal, early and
late systolic, and diastolic flow (2). In some patients, the early and late
systolic flow was difficult to separate and was not analyzed separately.
Eight of 11 patients with no or minimal atrioventricular valve regur-
gitation did have a (late) systolic velocity within the mean value 6 2SD
for normals. Our opinion is that the pulmonary vein flow patterns are
controlled by left heart mechanics.
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Reply
As Dr. Teien states in his letter, their study shows that patients with
univentricular hearts palliated with a Fontan total cavo-pulmonary
connection (TCPC) procedure have a pulmonary venous (PV) flow
pattern that is somewhat similar to that seen in normal biventricular
hearts. Specifically, they also observe four phases of PV flow. As in
normal patients, the early and late systolic flow is sometimes difficult to
separate with transthoracic recordings and therefore these two flows
were not analyzed separately. Because of the similarities of flow in
TCPC and normal hearts, the authors conclude that pulmonary venous
flow is controlled predominately by left heart mechanics. In our animal
study, we had concluded that the late systolic flow was influenced by
the pressure increase in the pulmonary venous system as a direct result
of right ventricular stroke volume.
After reviewing the article by Dr. Teien and associates, I agree that
TCPC hearts have pulmonary venous recordings with four phases.
However, as shown in their Table 1 and Table 2, the TCPC patients
tend to have lower systolic flow velocities and systolic flow velocity
intervals. Two explanations are possible. Because pulmonary venous
flow is the result of the pressure difference between pulmonary artery
and left atrial pressure, a reduced systolic fraction may occur if there
is a blunted rise in pulmonary venous pressure with systole, or
alternatively if there is an increased pressure rise in the left atrium
(usually due to left atrial noncompliance). Without direct pressure
measurement, I think it is impossible in the TCPC patients to know the
primary mechanism.
Overall, the conclusions made in both papers are not mutually
exclusive. Our data unquestionably shows there is a late systolic
pressure increase in the pulmonary venous system, which is a direct
result of RV stroke volume. In TCPC patients, the increase in pressure
is caused by a more constant and less pulsatile flow. Whether this latter
situation results in a tendency toward a lesser increase in late systolic
PV pressure and flow is speculative, but would actually support our
assertion that RV output is an important and additional determinant
of pulmonary venous systolic flow. On the other hand, the point is well
taken that once the PV reservoir is charged with volume and pressure,
alterations in “downstream” left atrial pressure due to mitral valve
opening and left ventricular filling help determine the characteristic
flow velocity pattern seen.
In summary, I thank Dr. Teien and associates for bringing to my
attention their important article on pulmonary venous blood flow in
TCPC hearts. I agree that even further study will be necessary to
determine the role right ventricular stroke volume plays in determining
pulmonary venous are late systolic flow that is independent from
“downstream” LA events.
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Seasonal Variations in the Incidence of Acute
Myocardial Infarction
We have read with interest the recent article by Spencer et al. (1),
which reported a higher incidence of acute myocardial infarction
(AMI) in winter than in summer months (1). We recently analyzed a
series of 9,571 computerized patient records from general practices in
the UK (General Practitioner Research Database) (2). We identified
1922 cases who had a first-time AMI at age 75 or younger in the
absence of recorded clinical risk factors for AMI. We matched 4
control subjects to each case on age, sex, general practice and calendar
time. We conducted both a case control and a case crossover analysis
to explore whether acute respiratory infections were associated with an
increased risk of developing an AMI. We assessed for all cases and
controls if and when they last had a chest infection recorded in the
patient record before the date when the case developed the AMI
(index date).
Our findings with regard to seasonal differences in the incidence of
AMIs were consistent with the results of Spencer et al. (1). We have
also observed the highest frequency of AMIs in January, and the lowest
in summer (June). We have further observed an approximately
threefold increased risk of developing an AMI in relation to an acute
respiratory tract infection within the 10 days immediately preceding
the index date. The risk was highest for patients who had a chest
infection within 5 days of the index date (OR 3.6, 95% CI 2.2–5.7), and
2103JACC Vol. 32, No. 7 LETTERS TO THE EDITOR
December 1998:2102–4
gradually decreased over a period of approximately two weeks towards
an OR of one (2).
The possible contribution of airway infections, which occur more
frequently in cold winter months than in summer, have not been listed
by Spencer et al. (1) among the possible explanations for the higher
incidence of AMIs in winter time. Evidence from smaller hospital-
based studies has already previously indicated that an association
between acute chest infections and AMI might exist (3–5). The
pathophysiologic mechanism of such an association is speculative and
could involve changes in circulating clotting factors, an increased risk
for acute rupture of arteriosclerotic plaque during a chest infection, or
a variety of other mechanisms. The role of acute and chronic infections
in the etiology of coronary heart disease and AMI needs to be better
understood; it might be one of the keys towards an explanation why
more AMIs occur in winter than in summer.
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Anticoagulation in Dilated Cardiomyopathy
We read with interest the recent review by Koniaris et al. (1)
concerning anticoagulation in dilated cardiomyopathy. Evidence from
published studies does not convincingly demonstrate the benefits of
anticoagulation in patients with dilated cardiomyopathy. As described
by Koniaris et al., (1) a prospective, randomized clinical trial of
long-term anticoagulation in patients with dilated cardiomyopathy is
feasible. However, studies employing hemostatic markers indicating a
biochemical imbalance between procoagulant and anticoagulant
mechanisms in the blood may be useful to evaluate the appearance of
thrombotic phenomena in these patients (2). By measuring plasma
levels of hemostatic markers, we previously found that, in patients with
dilated cardiomyopathy, plasma levels of fibrinopeptide A and
thrombin-antithrombin III complex, markers of coagulation activation
and thrombin generation, were significantly higher than those in
normal subjects (3). Their levels showed a positive correlation with left
ventricular end-diastolic volume and a negative correlation with frac-
tional shortening of the left ventricle. Although Koniaris et al. (1)
suggested that aspirin monotherapy may be beneficial for risk reduc-
tion of thromboembolism in patients with dilated cardiomyopathy,
plasma levels of platelet factor-4 and beta-thromboglobulin, markers
of platelet activation, were not elevated in these patients compared
with normal subjects. In addition, we previously observed that aspirin
monotherapy suppresses platelet function, but does not affect coagu-
lation activity (4). These findings support the premise that anticoagu-
lant therapy, rather than antiplatelet therapy, is more effective for the
prevention of systemic embolism in patients with dilated cardiomyop-
athy, particularly in those with severe left ventricular enlargement and
dysfunction.
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